發(fā)布時間：2019-05-12 17:50

【摘要】：目的:通過檢測原發(fā)性肝癌患者經肝動脈化療栓塞(TACE)治療前后血清血管內皮生長因子(VEGF)水平,探討原發(fā)性肝癌患者TACE治療前后血清VEGF水平變化與療效之間的關系。方法:選擇2013年1月至2014年6月在我院介入治療科接受TACE治療的原發(fā)性肝癌患者40例為研究對象,采用酶聯免疫吸附試驗(ELISA)分別檢測肝癌患者TACE治療前1d及術后28d的血清VEGF、分析肝癌患者血清VEGF水平與患者臨床基本資料、甲胎蛋白(AFP)及患者預后的關系。結果:40例肝癌患者TACE術前的血清VEGF水平為418.4±111.2pg/ml。HCC組患者TACE術前血清VEGF水平明顯高于肝硬化組及健康對照組,差異均具有統計學意義(t值分別為4.839和10.895,P均0.05)。肝癌患者血清VEGF水平與患者臨床基本資料均無明顯相關(P均0.05)。肝癌患者TACE術后28d VEGF水平療效較好組為424.6±103.2 pg/ml,較術前無明顯差異,差異無統計學意義(t值=0.403,P0.05),療效較差組術后28d VEGF水平為622.8±107.3 pg/ml,差異有統計學意義(t=2.098,P0.05)。肝癌患者術前VEGF水平與AFP、肝生化功能功指標無相關性(P均0.05)。將40例肝癌患者按TACE治療療效分為:療效較好組26例與療效較差組14例,療效較差組患者術后28d血清VEGF水平高于療效較好組,差異有統計學意義(P0.05),TACE治療前后血清VEGF水平變化率與術后腫瘤病灶碘油存積情況呈顯著相關性(r=-0.721,P0.05)。結論:肝癌患者血清VEGF水平高于肝硬化患者及健康人;血清VEGF水平與患者臨床資料無關;TACE術前血清VEGF水平與AFP及GGT、LDH、AFU、ALP等生化指標無明顯相關性;術后血清VEGF水平可以預測患者TACE治療療效。
[Abstract]:Objective: to detect the level of serum vascular endothelial growth factor (VEGF) in patients with primary liver cancer before and after (TACE) treatment, and to explore the relationship between the level of serum VEGF and the curative effect of patients with primary liver cancer before and after TACE treatment. Methods: from January 2013 to June 2014, 40 patients with primary liver cancer who received TACE treatment in the interventional therapy department of our hospital were selected as the subjects. Enzyme-linked immunosorbent assay (ELISA) was used to detect the relationship between serum VEGF level and clinical data, alpha-fetoprotein (AFP) and prognosis in patients with liver cancer one day before and 28 days after TACE treatment. Results: the serum VEGF level of 40 patients with liver cancer before TACE was 418.4 鹵111.2pg/ml.HCC group, which was significantly higher than that of liver sclerosis group and healthy control group before TACE. The difference was statistically significant (t = 4.839 and 10.895, P < 0.05). There was no significant correlation between serum VEGF level and basic clinical data in patients with liver cancer. There was no significant difference in the level of VEGF in patients with liver cancer 28 days after TACE compared with that before operation (t = 0.403, P 0.05). The level of VEGF was 622.8 鹵107.3 pg/ml, on the 28th day after operation in the group with poor curative effect. There was no significant difference in the level of VEGF between the two groups (t = 0.403, P 0.05). The difference was statistically significant (t 鈮，

本文編號：2475581